Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial

Publication | Closed Access

DOI

Citations

References

2023

Year

Hitt Sharma, Sameer Parekh, Pramod Pujari, Sunil Shewale, Shivani Desai, Neerja Bhatla, Smita Joshi, Sharmila Pimple, Anand Kawade, Latha Balasubramani,

The Lancet Oncology

VaccinationVaccine SafetyVaccinologyQuadrivalent Hpv VaccinePreventive MedicineCervical HealthHuman Papillomavirus VaccinesVaccine TestingVaccine EfficacyPhase 2/3Public HealthPolyvalent VaccineMedicineVaccine ResearchEpidemiology